Alex Green of The Oxford Club is pitching the “Millionaire-Maker Stock,” a Nobel-linked biotech story that we trace and test against the filings.
One promotion, several names — all of them point to the same pitch, and the same stock.
“Will You Be Ready for The Biggest Millionaire-Maker Event in 30 Years?” That’s the headline Alex Green of The Oxford Club is using to sell The #1 Millionaire-Maker Stock for 2026.
The pitch points to a Nobel-linked gene-editing company with an FDA-approved therapy, roughly $2 billion in liquid assets, no long-term debt, and takeover potential. A countdown says the offer expires today.
The stock is CRISPR Therapeutics AG, ticker CRSP. We’re 91/100 confident. The separate NVIDIA partner bonus points to Astera Labs, ticker ALAB, but with lower confidence.
The main trail is unusually specific: Nobel Prize-winning CRISPR/Cas9 technology, the CASGEVY therapy, a large cash position, and zero long-term debt. The promotion also brands the same idea as the “Millionaire-Maker Event,” “Generational Wealth Event,” and “The Biggest Millionaire-Maker Event in 30 Years.” Those are different labels for the same pitch.
The bonus trail names NVIDIA, Amazon, TSMC, Intel, Sutter Hill Ventures, 104% revenue growth, and a wiring bottleneck in AI data centers. Those clues point toward a semiconductor-connectivity company rather than another gene-editing biotech.
The headline stock is CRISPR Therapeutics AG (CRSP). The Nobel clue lands cleanly: the Nobel Prize awarded Emmanuelle Charpentier and Jennifer Doudna the 2020 Chemistry prize for developing CRISPR/Cas9 genome editing, and CRISPR Therapeutics’ filings identify Charpentier as a scientific founder whose CRISPR/Cas9 patent estate was licensed to the company.
CASGEVY makes the match even tighter. CRISPR Therapeutics co-developed the therapy with Vertex Pharmaceuticals, and the company’s filings describe CRISPR/Cas9 as a platform for precisely altering genomic DNA. The balance-sheet clues fit too: CRISPR Therapeutics reported roughly $2 billion in cash, cash equivalents, and marketable securities, while its 2024 and 2025 annual reports show no long-term-debt line.
The separate “Nvidia’s Secret Partner: This Single AI Stock Could Help Fund Your Retirement” bonus appears to be Astera Labs (ALAB), with 78/100 confidence. Astera’s NVIDIA collaboration, partnerships involving AWS, TSMC, and Intel, and its own language about connectivity bottlenecks all line up. Its 2025 third-quarter revenue was up 104% year over year. The loose screws are important: Sutter Hill’s cited ownership was a pre-IPO stake, not a current major holding in the latest proxy statements, and Astera’s roughly $54.4 billion market capitalization hardly makes it a small-cap stock.
The offer bundles a bonus report that teases its own stock. These get a sentence or two of copy each, so the evidence is much thinner than for the main pick and what follows is our best reading rather than a confident answer.
| Bonus report | Our best guess | Confidence |
|---|---|---|
| Nvidia’s Secret Partner: This Single AI Stock Could Help Fund Your Retirement | ALAB — Astera Labs, Inc. | 78/100 — solid |
The claim-by-claim checks below separate the clues that survive contact with Nobel Prize records, FDA materials, company filings, SEC filings, proxy statements, and market data from the ones that have been stretched on the way to the sales page.
| The promotion claims | Verdict | What we found |
|---|---|---|
| CRISPR Therapeutics uses Nobel Prize-winning gene-editing technology | Checks out | The Nobel Prize awarded Emmanuelle Charpentier and Jennifer Doudna the 2020 Chemistry prize for developing CRISPR/Cas9 genome editing, and CRISPR Therapeutics’ filings identify Charpentier as a scientific founder whose CRISPR/Cas9 patent estate was licensed to the company. |
| CRISPR Therapeutics can rewrite human DNA | Checks out | CRISPR Therapeutics’ annual report describes CRISPR/Cas9 as a platform for precisely altering genomic DNA, while the Nobel Prize describes CRISPR/Cas9 as a tool for modifying genomes. |
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The obvious question is: what does “today” actually attach to? The promotion showed a countdown and gave no exact date beyond today.
We received it on one separate day, August 3, 2026. That’s too thin a sample to say whether the deadline rolls, so there’s no expiration pattern to report yet.
The pitch’s central claim is simple: CRISPR won the Nobel Prize, CASGEVY proves the technology, the company has a fortress-like balance sheet, and that combination makes CRISPR Therapeutics the next millionaire-maker or a prime acquisition target.
The first three links mostly hold. CRISPR/Cas9 is genuine Nobel-recognized science, CASGEVY is a real FDA-approved CRISPR-based therapy, and CRISPR Therapeutics has substantial liquid assets with no disclosed long-term debt. But the promotion inflates the FDA point: CRISPR Therapeutics co-developed one approved therapy with Vertex, while the FDA approval is held by Vertex. “Therapies” turns one into several.
The weakest link is the leap from promising platform and clean balance sheet to “prime acquisition target.” CRISPR Therapeutics’ annual reports and investor releases discuss CASGEVY, its pipeline, and its finances; they don’t disclose a sale process, takeover bid, or formal strategic review. That makes acquisition potential a story about what might happen, not a fact established by the filings. The roughly $2 billion figure is also liquid assets, not cash alone.
On its own merits, CRSP is a real biotech with an approved therapy, an important technology platform, and meaningful financial resources. Those are serious ingredients, but they don’t turn a millionaire-maker headline into an earnings forecast. ALAB has the cleaner partnership evidence in the bonus pitch, especially around NVIDIA and AI connectivity, but the stale Sutter Hill attribution and “small stock” label weaken the sales argument there too.
How confident are we? 91 out of 100. We identified CRISPR Therapeutics AG (CRSP) from the promotion's own clues and checked 15 of its claims against filings, earnings calls, ownership records, market data and public reporting. This is our analysis, not the publisher's disclosure — we have no relationship with them.
Knowing which stock it is only gets you halfway. We score CRSP on valuation, profitability, growth, financial health and momentum — and reach our own conclusion, independent of how it was sold to you.
See the CRSP data →Independent of the promotion — our own numbers, score and analysis.
Everything we track on CRSP in one place — the TickerSpark Score, price charts, key financials, and our latest coverage.
| CRISPR Therapeutics has FDA-approved therapies |
| Contradicted |
| CRISPR Therapeutics co-developed CASGEVY, the first FDA-approved CRISPR-based therapy, with Vertex Pharmaceuticals; the FDA approval is held by Vertex, and the record supports one approved therapy rather than multiple FDA-approved therapies. |
| CRISPR Therapeutics has roughly $2 billion in cash | Overstated | CRISPR Therapeutics’ 2024 Form 10-K reported $1.9038 billion in cash, cash equivalents, and marketable securities, and its 2025 Form 10-K reported $1.9758 billion; the roughly $2 billion figure is liquid assets, not cash alone. |
| CRISPR Therapeutics has zero long-term debt | Checks out | CRISPR Therapeutics’ 2024 and 2025 annual-report balance sheets show no long-term-debt line; the liabilities disclosed are operating and lease-related obligations rather than funded long-term borrowings. |
| CRISPR Therapeutics is a prime acquisition target | Can't verify | CRISPR Therapeutics’ annual reports and investor releases document CASGEVY, its pipeline, and its balance sheet, but they do not disclose a sale process, takeover bid, or formal strategic review establishing that it is a prime acquisition target. |
| NVIDIA is partnering with Astera Labs | Checks out | Astera Labs announced an expanded collaboration with NVIDIA for the NVLink Fusion ecosystem and said NVIDIA platforms including HGX, MGX, and NVL72 have been supported by Astera’s PCIe connectivity solutions. |
| Amazon is partnering with Astera Labs | Checks out | Astera Labs’ partner FAQ lists AWS among its design and manufacturing partners, and Astera’s 2026 SEC filing documents a transaction agreement with Amazon tied to potential purchases of Astera connectivity products. |
| TSMC is partnering with Astera Labs | Checks out | Astera Labs’ website identifies TSMC as an industry partner, and a TSMC North America statement on Astera’s About page says the companies collaborated to deliver Aries Smart Retimers. |
| Intel is partnering with Astera Labs | Checks out | Astera Labs’ interoperability page says it collaborated with Intel to support 5th Gen Intel Xeon Scalable processors using PCIe and CXL solutions. |
| Sutter Hill Ventures backed NVIDIA in the 1990s | Checks out | NVIDIA’s 1999 proxy listed entities associated with Sutter Hill Ventures as beneficial owners of 7.3% of NVIDIA, and NVIDIA identifies former Sutter Hill managing director Tench Coxe as an early board member who joined in 1993. |
| Sutter Hill Ventures is a major shareholder in Astera Labs | Overstated | Astera Labs’ March 2024 S-1/A listed Sutter Hill-affiliated entities with 22.4 million shares, or 13.7% before the IPO, but Astera’s 2025 and 2026 proxy statements do not list Sutter Hill among current 5% stockholders; the promotion presents a historical pre-IPO stake as current. |
| Astera Labs revenue is up 104% year over year | Checks out | Astera Labs’ November 2025 third-quarter earnings release reported $230.6 million of revenue, up 104% year over year; the 104% figure applies to Q3 2025, while full-year 2025 growth was 115%. |
| Astera Labs solves the wiring bottleneck connecting NVIDIA’s chips | Checks out | Astera Labs says connectivity is becoming the bottleneck in thousand-GPU AI fabrics, and its product filings say Taurus smart cable modules remove rack-level Ethernet connectivity bottlenecks; its NVIDIA materials position these products for NVIDIA Blackwell and Rubin platforms. |
| Astera Labs is a small tech stock | Overstated | Astera Labs closed at $317.23 with a market capitalization of about $54.4 billion; that is far above the roughly $300 million to $2 billion range normally used for small-cap companies, although it is small relative to NVIDIA and other mega-cap AI companies. |
Cancel anytime
Mark Skousen’s The Skousen Report, published by The Oxford Club, is promoting Elon's Hit List. We trace its three targets and test the acquisition case.
Marc Lichtenfeld's Oxford Income Letter promotes the “SpaceX Royalty” Portfolio. We identify the two companies and test the promised income claim.
Alexander Green and The Oxford Club are pitching the Secret ASI Fund through The Oxford Communiqué. We trace the headline's hidden company and test its AI claims.